Charles River provides comprehensive bioanalytical support for all stages of product development, from early discovery and preclinical studies (non-GLP and GLP) through all phases of clinical development. Our experienced chemists develop, validate and apply quantitative methods for the determination of pharmaceutical compounds in biological samples, from small molecules to larger peptides. Methods can be transferred from sponsor laboratories and feasibility studies performed to confirm suitability for purpose.
Our bioanalytical chemists use advanced technologies, such as 96-well plate automated sample extraction and high-throughput microcolumn analysis, to rapidly analyze sample batches of varying sizes at an industry-leading pace. Our laboratories have the latest analytical equipment to measure drug and metabolite concentrations in biological matrices such as plasma, serum, CSF, urine and tissue using a wide range of different techniques. All studies are supported by a validated Watson™ LIMS for sample and data management.
- LC-MS and GC-MS
- HPLC and GC
- Immunoassay techniques such as ELISA, RIA, EIA, IRMA, and DELFIA
- AAS for measurement of total metal content in biological samples
To assist in quantitative bioanalysis, our chemical synthesis group can produce non-labeled or stable isotope labeled compounds, such as deuterated or carbon-13 analogues, for use as assay internal standards. They can also assist with metabolite identification, profiling, and synthesis.
Related Educational Articles
Subject matter experts are available to answer any questions that you may have regarding bioanalysis services. Click here to submit your specific question, and our scientists will get back to you shortly.